BioCentury | Dec 8, 2017
Company News

Medigene sells U.S. rights for Veregen

...SB03). Financial terms were not disclosed. Medigene will exclusively supply Veregen to Sandoz's dermatology business, Fougera Pharmaceuticals Inc....
BioCentury | Apr 28, 2014
Strategy

Bigger is better

...animal health (9%) and vaccines and diagnostics (6%). In 2012, Novartis acquired dermatology generics company Fougera Pharmaceuticals Inc....
BioCentury | Jul 15, 2013
Company News

Lantheus management update

...North Billerica, Mass. Business: Diagnostic Hired: John Golubieski as interim CFO, formerly CFO of Fougera Pharmaceuticals Inc....
BioCentury | Feb 4, 2013
Company News

Lantheus management update

...Mass. Business: Diagnostic Hired: Jeffrey Bailey as president, CEO and a director, formerly COO of Fougera Pharmaceuticals Inc....
BioCentury | Sep 17, 2012
Finance

Banker tracks

...director focused on the pharmaceutical sector. He was SVP of business development and strategy at Fougera Pharmaceuticals Inc....
...joined Avista Capital Partners as a healthcare industry executive. He was president and CEO or Fougera Pharmaceuticals Inc....
BioCentury | Jul 30, 2012
Company News

Fougera Pharmaceuticals Inc., Novartis deal

...acquisition of dermatology generics company Fougera for $1.5 billion in cash (see BioCentury, May 7). Fougera Pharmaceuticals Inc....
BioCentury | May 7, 2012
Company News

Fougera, Novartis deal

...Sandoz Ltd. generics unit will acquire dermatology generics company Fougera for $1.5 billion in cash. Fougera...
...last year by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Tokyo, Japan) for €9.6 billion ($13.8 billion). Fougera's...
...Capital Funds; DLJ Merchant Banking Partners; and Avista Capital Partners (see BioCentury, Oct. 3, 2011). Fougera...
BioCentury | May 3, 2012
Company News

Sandoz to acquire former Nycomed dermatology unit

...NYSE:NVS; SIX:NOVN), will acquire dermatology generics company Fougera Pharmaceuticals Inc. (Melville, N.Y.) for $1.5 billion in cash. Fougera...
...acquisition last year by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for EUR 9.6 billion ($13.8 billion). Fougera's...
...DLJ Merchant Banking Partners; and Avista Capital Partners (see BioCentury Extra, Aug. 1, 2011) . Fougera...
Items per page:
1 - 8 of 8
BioCentury | Dec 8, 2017
Company News

Medigene sells U.S. rights for Veregen

...SB03). Financial terms were not disclosed. Medigene will exclusively supply Veregen to Sandoz's dermatology business, Fougera Pharmaceuticals Inc....
BioCentury | Apr 28, 2014
Strategy

Bigger is better

...animal health (9%) and vaccines and diagnostics (6%). In 2012, Novartis acquired dermatology generics company Fougera Pharmaceuticals Inc....
BioCentury | Jul 15, 2013
Company News

Lantheus management update

...North Billerica, Mass. Business: Diagnostic Hired: John Golubieski as interim CFO, formerly CFO of Fougera Pharmaceuticals Inc....
BioCentury | Feb 4, 2013
Company News

Lantheus management update

...Mass. Business: Diagnostic Hired: Jeffrey Bailey as president, CEO and a director, formerly COO of Fougera Pharmaceuticals Inc....
BioCentury | Sep 17, 2012
Finance

Banker tracks

...director focused on the pharmaceutical sector. He was SVP of business development and strategy at Fougera Pharmaceuticals Inc....
...joined Avista Capital Partners as a healthcare industry executive. He was president and CEO or Fougera Pharmaceuticals Inc....
BioCentury | Jul 30, 2012
Company News

Fougera Pharmaceuticals Inc., Novartis deal

...acquisition of dermatology generics company Fougera for $1.5 billion in cash (see BioCentury, May 7). Fougera Pharmaceuticals Inc....
BioCentury | May 7, 2012
Company News

Fougera, Novartis deal

...Sandoz Ltd. generics unit will acquire dermatology generics company Fougera for $1.5 billion in cash. Fougera...
...last year by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Tokyo, Japan) for €9.6 billion ($13.8 billion). Fougera's...
...Capital Funds; DLJ Merchant Banking Partners; and Avista Capital Partners (see BioCentury, Oct. 3, 2011). Fougera...
BioCentury | May 3, 2012
Company News

Sandoz to acquire former Nycomed dermatology unit

...NYSE:NVS; SIX:NOVN), will acquire dermatology generics company Fougera Pharmaceuticals Inc. (Melville, N.Y.) for $1.5 billion in cash. Fougera...
...acquisition last year by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for EUR 9.6 billion ($13.8 billion). Fougera's...
...DLJ Merchant Banking Partners; and Avista Capital Partners (see BioCentury Extra, Aug. 1, 2011) . Fougera...
Items per page:
1 - 8 of 8